Big Rebates Already A Big Factor For Drugs On Medicare Negotiation List

 
• By Cathy Kelly

Long-awaited list has a couple of surprises that are expected to face biosimilar competition either before negotiated prices are implemented in 2026 or during that year.

over inflated drugs
Many of the drugs picked by Medicare appear to have list prices inflated by rebates. • Source: Shutterstock

More from Pink Sheet

More from Market Access